Cataplexy
FDA Panel Considers GHB For Treating Narcolepsy-Related Condition
Published in Medical Letter on the CDC and FDA, July 1st, 2001
The panel convened by the U.S. Food and Drug Administration (FDA) had been asked to consider whether prescription sales should be permitted for GHB - gamma hydroxy butyrate - under the brand name Xyrem.
The committee voted 6-3 that the manufacturer has shown that the drug is useful in treating cataplexy, a complication that can cause people to suddenly collapse when their muscles lose strength.
The vote, in effect, endorses sales of the drug. The FDA is not...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Epidemiology
UN Says HIV/AIDS Epidemic Is Still In Early Stages - Prevention
CDC Outlines New Strategic Plan To Thwart HIV Infection - At-Risk Populations
New CDC Study Finds High Rates Of HIV Infection Among Young Gay And Bisexual Men - Diet and Nutrition
Proposed Change To Food Labels Would Help Consumers Wanting To Follow New Cholesterol Guidelines - Foodborne Illness
Microbiological Testing Would Shore Up Restaurant Inspections - Complementary and Alternative Medicine
Traditional Practitioners In China Urged To Modernize - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
